NAUT – nautilus biotechnology, inc. (US:NASDAQ)
Stock Stats
News
With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future [Yahoo! Finance]
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $1.75 price target on the stock.
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
Form 144 Nautilus Biotechnology, Filed by: Godwin Mary E.
Form 144 Nautilus Biotechnology, Filed by: Godwin Mary E.
Form 144 Nautilus Biotechnology, Filed by: Godwin Mary E.
Form 144 Nautilus Biotechnology, Filed by: Godwin Mary E.
Form 144 Nautilus Biotechnology, Filed by: Godwin Mary E.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.